Mast Therapeutics, Inc. (SVRA) Given New $32.00 Price Target at Roth Capital
Mast Therapeutics, Inc. (NASDAQ:SVRA) had its price target reduced by Roth Capital from $40.00 to $32.00 in a research note issued to investors on Tuesday. They currently have a buy rating on the stock.
Several other equities research analysts also recently weighed in on the company. Canaccord Genuity reaffirmed a buy rating and set a $18.00 price target on shares of Mast Therapeutics in a research report on Monday, July 17th. Zacks Investment Research downgraded Mast Therapeutics from a buy rating to a hold rating in a research report on Friday, September 15th. Finally, Jefferies Group LLC began coverage on Mast Therapeutics in a research report on Friday, September 22nd. They set a buy rating and a $20.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and a consensus price target of $21.30.
Mast Therapeutics (NASDAQ SVRA) traded down 1.50% during trading on Tuesday, reaching $9.17. The company had a trading volume of 52,889 shares. The stock has a 50 day moving average price of $9.05 and a 200 day moving average price of $6.77. The firm’s market capitalization is $221.94 million. Mast Therapeutics has a 52 week low of $4.60 and a 52 week high of $16.23.
In related news, Director Yuri Pikover purchased 50,000 shares of the business’s stock in a transaction on Friday, October 27th. The shares were bought at an average cost of $7.85 per share, with a total value of $392,500.00. Following the transaction, the director now owns 150,000 shares of the company’s stock, valued at $1,177,500. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 6.93% of the stock is currently owned by company insiders.
Mast Therapeutics Company Profile
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Receive News & Stock Ratings for Mast Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc. and related stocks with our FREE daily email newsletter.